Auvinen A, Elovainio L, Hakama M
Finnish Cancer Registry, Helsinki, Finland.
Breast Cancer Res Treat. 1996;38(2):161-8. doi: 10.1007/BF01806670.
A prospective study was conducted to investigate the possible effect of breast self-examination (BSE) on cause-of-death-specific survival rate of breast cancer patients. Six hundred and four breast cancer patients diagnosed in 1984-1986 in Finland, and applying for breast prostheses, were interviewed about both their BSE practices prior to cancer diagnosis and the actual method of tumor detection. No clear differences were observed in the stage distribution or cause of death-specific five-year survival rates between individuals with different BSE practices. After adjustment for potential confounders in the Cox proportional hazards analysis, no differences in risk of breast cancer death were observed for those who performed BSE monthly as compared to those who practised BSE less frequently or not at all. When the method of detection was taken into account, it turned out that only 34 (7.6 %) of the 448 regular BSE practisers had actually detected their cancers by means of BSE. Furthermore, no survival advantage was associated with detection of breast cancer by means of BSE. Those BSE practisers whose cancer was detected by BSE had a similar or slightly worse prognosis compared to BSE practisers whose cancer had been detected by other means. Our results suggest that BSE practice is not beneficial in terms of breast cancer survival, nor is detection of breast cancer by means of BSE. Conclusive evidence should, however, be obtained from prospective randomized studies of breast cancer mortality.
开展了一项前瞻性研究,以调查乳房自我检查(BSE)对乳腺癌患者死因特异性生存率的可能影响。对1984年至1986年在芬兰诊断出并申请乳房假体的604例乳腺癌患者,就其癌症诊断前的BSE做法和肿瘤实际检测方法进行了访谈。不同BSE做法的个体之间,在分期分布或死因特异性五年生存率方面未观察到明显差异。在Cox比例风险分析中对潜在混杂因素进行调整后,与较少频繁进行BSE或根本不进行BSE的人相比,每月进行BSE的人在乳腺癌死亡风险上没有差异。当考虑检测方法时,结果发现,在448名定期进行BSE的人中,只有34人(7.6%)实际上通过BSE检测出了他们的癌症。此外,通过BSE检测出乳腺癌并没有生存优势。与通过其他方式检测出癌症的BSE践行者相比,通过BSE检测出癌症的BSE践行者的预后相似或略差。我们的结果表明,就乳腺癌生存而言,BSE做法并无益处,通过BSE检测乳腺癌也无益处。然而,确凿的证据应来自关于乳腺癌死亡率的前瞻性随机研究。